# Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

> **NCT00660972** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 40 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Raltegravir
- **DRUG:** Emtricitabine/tenofovir disoproxil fumarate

## Key facts

- **NCT ID:** NCT00660972
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2009-01
- **Final completion:** 2010-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660972, "Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00660972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*